Zentalis Pharmaceuticals Inc’s recent filing unveils that its Former Chief Medical Officer Diana Hausman acquired Company’s shares for reported $28294.0 on Oct 31 ’24. In the deal valued at $2.86 per share,9,888 shares were bought.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Vultaggio Vincent sold 1,603 shares, generating $5,098 in total proceeds. Upon selling the shares at $3.18, the Principal Accounting Officer now owns 33,855 shares.
Before that, Gallagher Cam sold 9,597 shares. Zentalis Pharmaceuticals Inc shares valued at $114,972 were divested by the President, Interim CFO at a price of $11.98 per share. As a result of the transaction, Gallagher Cam now holds 633,680 shares, worth roughly $1.96 million.
Wedbush upgraded its Zentalis Pharmaceuticals Inc [ZNTL] rating to a Neutral from a an Underperform in a research note published recently. A number of analysts have revised their coverage, including UBS’s analysts, who decreased its forecast for the stock in mid June from “a Buy” to “a Neutral”. Wells Fargo also remained covering ZNTL and has decreased its forecast on June 18, 2024 with a “an Equal weight” recommendation from previously “an Overweight” rating. Wedbush revised its rating on June 18, 2024. It rated ZNTL as “an Underperform” which previously was an “a Neutral”.
Price Performance Review of ZNTL
On Friday, Zentalis Pharmaceuticals Inc [NASDAQ:ZNTL] saw its stock fall -1.28% to $3.09. Over the last five days, the stock has lost -11.71%. Zentalis Pharmaceuticals Inc shares have fallen nearly -79.60% since the year began. Nevertheless, the stocks have fallen -79.63% over the past one year. While a 52-week high of $18.07 was reached on 02/28/24, a 52-week low of $2.66 was recorded on 10/31/24. SMA at 50 days reached $3.32, while 200 days put it at $7.01.
Levels Of Support And Resistance For ZNTL Stock
The 24-hour chart illustrates a support level at 3.00, which if violated will result in even more drops to 2.91. On the upside, there is a resistance level at 3.19. A further resistance level may holdings at 3.29. The Relative Strength Index (RSI) on the 14-day chart is 42.20, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.24, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 91.92%. Stochastics %K at 21.34% indicates the stock is a holding.
How much short interest is there in Zentalis Pharmaceuticals Inc?
A steep rise in short interest was recorded in Zentalis Pharmaceuticals Inc stocks on 2024-11-29, dropping by -2.38 million shares to a total of 4.67 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-31 was 7.05 million shares. There was a decline of -51.03%, which implies that there is a negative sentiment for the stock.
